Skip to main content
. 2022 Oct 20;12:1012391. doi: 10.3389/fonc.2022.1012391

Figure 1.

Figure 1

Outcome Survival Summary. (A) Median PFS was 6.8 months with 95% CI (2.5, 9.2). (A) 8/27 (29.6%) patients had died, and all deaths were attributed to metastatic breast cancer. The median survival had not been reached, and the 12-month OS/disease-specific survival (DSS) rate was 67.7%.